GSK reports fall in profit over Zantac fallout—but boosts 2031 revenue target to £40 billion due to boom in cancer drug sales


GettyImages 2173420062 e1738748622764
“We expect another year of profitable growth in 2025, and have further improved our long-term outlook,” said CEO Walmsley. Read More

Leave a Comment

You cannot copy content of this page